| HOME >> BIOLOGY >> TECHNOLOGY |
__________
No later than 8 days before the Annual General Meeting the agenda, the complete proposals as well as the Annual Report will be made available to the Company's shareholders at the Company's offices at Toldbodgade 33, 1253 Copenhagen K, Denmark. The documents are also available at the Company's website, http://www.genmab.com.
Admission card: Any shareholder is entitled to attend the Annual General Meeting after having submitted a request for an admission card no later than Monday April 21, 2008 at 4:00 PM CEST. Admission cards may be requested by contacting VP Investor Services A/S, telephone +45-43-58-88-66 or fax +45-43-58-88-67. Alternatively via http://www.genmab.com or http://www.uk.vp.dk/agm.
Shareholders who do not expect to be able to participate in the General Meeting may grant proxy to the Board of Directors or to a person appointed by the shareholder. A form for submitting votes by proxy may be obtained via http://www.genmab.com. The shareholders exercise their financial rights through their own deposit banks, cf. Section 73,5(2) of the Danish Public Companies Act.
Any shareholder, to whom admission card already has been issued, but who is prevented from attending the Annual General Meeting is kindly asked to notify the company - preferably before Tuesday April 22, 2008.
Copenhagen, April 7, 2008 On behalf of the Board of Directors
MICHAEL B. WIDMER Chairman
About Genmab A/S
Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
cutting-edge antibody technology, Genmab's
'/>"/>
| SOURCE Genmab A/S Copyright©2008 PR Newswire. All rights reserved |